Biophytis (BPTS)

NASDAQ
8.70
+0.01(+0.12%)
  • Volume:
    303
  • Bid/Ask:
    8.01/8.66
  • Day's Range:
    8.70 - 8.70

BPTS Overview

Prev. Close
8.69
Day's Range
8.7-8.7
Revenue
-
Open
8.7
52 wk Range
8.4-18.5
EPS
-
Volume
303
Market Cap
-
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,226
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
-
Next Earnings Date
-
What is your sentiment on Biophytis?
or
Market is currently closed. Voting is open during market hours.

Biophytis News

Biophytis Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellSell
Technical IndicatorsNeutralBuySellStrong SellBuy
SummaryNeutralNeutralSellStrong SellNeutral

Biophytis Company Profile

Biophytis Company Profile

Employees
25

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.

Read More
  • So nice!! C´mon
    0
    • Let's go!
      0
      • welcome biophytis.
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.